Show simple item record

dc.contributor.author Perroud, Herman Andrés
dc.contributor.author Rico, Maria Jose
dc.contributor.author Alasino, Carlos
dc.contributor.author Queralt, Fransisco
dc.contributor.author Mainetti, Leandro Ernesto
dc.contributor.author Pezzotto, Stella Maris
dc.contributor.author Rozados, Viviana Rosa
dc.contributor.author Scharovsky, Olga Graciela
dc.date.available 2017-08-03T18:01:10Z
dc.date.issued 2013-03
dc.identifier.citation Perroud, Herman Andrés; Rico, Maria Jose; Alasino, Carlos; Queralt, Fransisco ; Mainetti, Leandro Ernesto; et al.; Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients; Future Medicine; Future Oncology; 9; 3; 3-2013; 451-462
dc.identifier.issn 1479-6694
dc.identifier.uri http://hdl.handle.net/11336/21817
dc.description.abstract Metronomic chemotherapy (MCT), the chronic administration, at regular intervals, of low doses of chemotherapeutic drugs without extended rest periods, allows chronic treatment with therapeutic efficacy and low toxicity. Our preclinical results suggested that combined MCT with cyclophosphamide and celecoxib could inhibit breast cancer growth. The aim of this study was to determine the toxicity, safety and efficacy of oral MCT with cyclophosphamide 50 mg per orem daily and celecoxib 400 mg (200 mg per orem two-times a day) in advanced breast cancer patients. During the first stage of the study, the therapeutic response consisted of prolonged stable disease for ≥24 weeks in six out of 15 (40%) patients with a median duration of 37.5 weeks and a partial response in one out of 15 (response rate: 6.7%) patients lasting 6 weeks . The overall clinical benefit rate was 46.7%. The median time to progression was 14 weeks. Progression-free survival at 24 weeks was 40% and the 1-year overall survival rate was 46.7%. The adverse events were mild (gastric, grade 1; and hematologic, grade 1 or 2). No grade 3 or 4 toxicities were associated with the treatment. Evaluation of patients’ quality of life showed no changes during the response period. MCT with cyclophosphamide plus celecoxib is safe and shows a therapeutic effect in advanced breast cancer patients.
dc.format application/pdf
dc.language.iso eng
dc.publisher Future Medicine
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject BREAST CANCER
dc.subject METRONOMIC CHEMOTHERAPY
dc.subject CYCLOPHOSPHAMIDE
dc.subject CELECOXIB
dc.subject.classification Reumatología
dc.subject.classification Medicina Clínica
dc.subject.classification CIENCIAS MÉDICAS Y DE LA SALUD
dc.title Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients
dc.type info:eu-repo/semantics/article
dc.type info:ar-repo/semantics/artículo
dc.type info:eu-repo/semantics/publishedVersion
dc.date.updated 2017-07-21T19:06:23Z
dc.journal.volume 9
dc.journal.number 3
dc.journal.pagination 451-462
dc.journal.pais Reino Unido
dc.journal.ciudad Londres
dc.description.fil Fil: Perroud, Herman Andrés. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Escuela de Ciencias Médicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
dc.description.fil Fil: Rico, Maria Jose. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Escuela de Ciencias Médicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
dc.description.fil Fil: Alasino, Carlos. Instituto de Oncología de Rosario; Argentina
dc.description.fil Fil: Queralt, Fransisco. Instituto de Oncología de Rosario; Argentina
dc.description.fil Fil: Mainetti, Leandro Ernesto. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Escuela de Ciencias Médicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
dc.description.fil Fil: Pezzotto, Stella Maris. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Escuela de Ciencias Médicas; Argentina
dc.description.fil Fil: Rozados, Viviana Rosa. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Escuela de Ciencias Médicas; Argentina
dc.description.fil Fil: Scharovsky, Olga Graciela. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Escuela de Ciencias Médicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
dc.journal.title Future Oncology
dc.relation.alternativeid info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.2217/fon.12.196
dc.relation.alternativeid info:eu-repo/semantics/altIdentifier/url/https://www.futuremedicine.com/doi/10.2217/fon.12.196


Archivos asociados

Icon
Blocked Acceso no disponible

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/restrictedAccess Excepto donde se diga explícitamente, este item se publica bajo la siguiente descripción: Creative Commons Attribution-NonCommercial-ShareAlike 2.5 Unported (CC BY-NC-SA 2.5)